Results 211 to 220 of about 14,094 (223)

Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?

Journal of Arthroplasty, 2023
Matthew Magruder, Mitchell Ng, Vincent Yao   +2 more
exaly  

Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2023
Soyoung Shin, Hyun Seok Oh, Beom Soo Shin   +2 more
exaly  

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Diabetes Care, 2022
Carel Le Roux, Ildikó Lingvay, Juan Frías   +2 more
exaly  

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations

Drug Design, Development and Therapy, 2022
Ariana Chao, Thomas Wadden, Jena Shaw Tronieri   +2 more
exaly  

Semaglutide as a promising antiobesity drug

Obesity Reviews, 2019
Dimitrios Kiortsis, Georgios Christou, John Blundell   +2 more
exaly  

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

European Journal of Pharmaceutical Sciences, 2017
Inga Bjørnsdottir, Lene Jensen
exaly  

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Diabetes Care, 2018
Ildikó Lingvay, Andrew Ahmann, Anders Gaarsdal Holst   +2 more
exaly  

Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Journal of Clinical Pharmacology, 2015
Lene Jensen, Christoph Kapitza
exaly  

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Lancet, The, 2019
Ildikó Lingvay, Motohiro Sasaki, Richard Pratley   +2 more
exaly  

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Diabetes Care, 2019
Ildikó Lingvay, Janusz Gumprecht, Julio Rosenstock   +2 more
exaly